Ignite Creation Date:
2024-05-06 @ 6:21 PM
Last Modification Date:
2024-10-26 @ 2:46 PM
Study NCT ID:
NCT05631795
Status:
RECRUITING
Last Update Posted:
2024-03-20
First Post:
2022-11-21
Brief Title:
Study to Assess the Safety of Alpelisib Plus Fulvestrant in Men and Post-menopausal Women With HR-positive HER2-negative Advanced Breast Cancer aBC With PIK3CA Mutation Whose Disease Progressed on or After Endocrine Treatment
Sponsor:
Organization:
Novartis
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
100
Enrollment Type:
ESTIMATED
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE4 |
Observational Models:
Time Perspective List:
Who Masked List: